Hemab ApS

Hemab ApS is a Danish clinical-stage biotechnology company focused on developing targeted therapies for bleeding disorders that have long lacked adequate treatment options. The company is headquartered in Frederiksberg, Denmark, and operates under the public-facing name Hemab Therapeutics. Its stated mission is to "reimagine the treatment of blood coagulation disorders to sustain life and human resilience," guided by the philosophy that "All Patients Matter." Hemab's therapeutic focus centers on coagulation conditions where research and innovation have historically been limited, including Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding. The company describes these as conditions where many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Hemab positions itself as a franchise builder in rare bleeding disorders, aiming to "leapfrog" existing therapeutics by combining advances in biology, drug modality, and care delivery. The company states that it is modality agnostic, adopting multiple validated technologies when designing product candidates and programs. Its development approach is informed by comprehensive natural history studies that seek to capture patient experiences often missed in standard clinical literature, such as the anxiety of unpredictable bleeding and the careful planning required for everyday activities. Hemab's pipeline includes sutacimig, which has been studied in Glanzmann thrombasthenia and Factor VII deficiency; HMB-002 in Von Willebrand Disease; and HMB-003 for heavy menstrual bleeding. The company has advanced these programs into clinical trials, including a Phase 1 trial of HMB-003 and Phase 2 studies in Glanzmann thrombasthenia. As a corporate entity, Hemab has attracted investor attention and has announced an upsized initial public offering, indicating a transition toward public-market funding. It has also raised a Series C round to advance next-generation bleeding disorder therapies. The company maintains an active clinical and scientific presence, presenting data at the ISTH congresses and enrolling participants in studies such as the VELORA Pioneer Phase 1/2 study and the VELORA Discover screening study. Its board of directors has been strengthened with appointments such as Keli Walbert. Hemab's activities reflect a broader effort to address neglected coagulation disorders through targeted, patient-informed therapeutic development.

Hemab ApS is a Danish biotechnology company headquartered in Frederiksberg, Denmark. It operates as a clinical-stage developer of therapies for bleeding disorders, with a focus on conditions that have historically received limited research attention. The company's public communications emphasize a mission to "reimagine the treatment of blood coagulation disorders" and a philosophy that "All Patients Matter." Hemab's therapeutic strategy is built around addressing coagulation disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding. The company states that for decades certain bleeding disorders have remained "in the shadows" as research and innovation focused elsewhere, and that many patients experience significant life-long disease burden due to a lack of available prophylactic therapies or limitations of existing treatments. Hemab describes its approach as starting with the experts who understand these conditions most intimately—the people living with them every day. Through comprehensive natural history studies, the company seeks to reveal aspects of disease experience that clinical literature often misses, such as the anxiety of unpredictable bleeding and the careful planning required for everyday activities. This patient-informed understanding is then used to match pharmacological targets with suitable technologies. Hemab states that it is modality agnostic, adopting multiple validated technologies when designing product candidates and programs. Its stated goals for these therapies include stabilizing essential coagulation proteins from premature breakdown, enabling these proteins to accumulate to levels that prevent bleeding, and playing a critical role in disease management. The company has advanced a pipeline of product candidates into clinical development. Sutacimig has been studied in Glanzmann thrombasthenia and Factor VII deficiency, with clinical and preclinical data presented at the ISTH 2026 Congress and interim Phase 2 data presented at ISTH 2025. HMB-002 has generated first clinical data in Von Willebrand Disease, also presented at ISTH 2026. HMB-003 is being developed for heavy menstrual bleeding, with a Phase 1 clinical trial that has dosed its first participant. Hemab has also initiated the VELORA Pioneer Phase 1/2 study and the VELORA Discover screening study, both of which are enrolling participants. A Phase 2 study in Glanzmann thrombasthenia has been fully enrolled. Hemab has attracted external investment and has taken steps toward public-market participation. The company announced the pricing of an upsized initial public offering, and it raised a Series C round to advance next-generation bleeding disorder therapies. Its board of directors has been strengthened with the appointment of Keli Walbert. The company maintains an active scientific presence through presentations at the ISTH congresses. As of the available evidence, Hemab remains an active clinical-stage biotechnology company focused on rare bleeding disorders.

• Hemab raises Series C to advance next-generation bleeding disorder therapies

  [1]Hemab - A bleeding disorder companyhemab.com
• Hemab announces pricing of upsized initial public offering

  [1]Hemab - A bleeding disorder companyhemab.com
• First clinical data on HMB-002 in Von Willebrand Disease

  [1]Hemab - A bleeding disorder companyhemab.com
• Interim Phase 2 data on sutacimig presented at ISTH 2025

  [1]Hemab - A bleeding disorder companyhemab.com
• Phase 2 Study in GT Fully Enrolled

  [1]Hemab - A bleeding disorder companyhemab.com
• Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003 for Heavy Menstrual Bleeding

  [1]Hemab - A bleeding disorder companyhemab.com
• Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

  [1]Hemab - A bleeding disorder companyhemab.com
• Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

  [1]Hemab - A bleeding disorder companyhemab.com
• Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert

  [1]Hemab - A bleeding disorder companyhemab.com

Clinical-stage biotechnology company developing targeted therapies for rare bleeding disorders with unmet needs, guided by patient-centric natural history research and a modality-agnostic development approach.

• Sutacimig

  Clinical-stage therapeutic candidate studied in Glanzmann thrombasthenia and Factor VII deficiency; clinical and preclinical data presented at ISTH 2026 and interim Phase 2 data at ISTH 2025.

• HMB-002

  Therapeutic candidate for Von Willebrand Disease; first clinical data presented at ISTH 2026.

• HMB-003

  Therapeutic candidate for heavy menstrual bleeding; Phase 1 clinical trial first participant dosed.

1. 1Hemab - A bleeding disorder companyhemab.com
2. 2About Hemab | Rare Bleeding Disorder Researchhemab.com
3. 3Hemab ApS (Denmark) - Wikidatawikidata.org